Navigation Links
Dendreon Announces Plans to Seek Marketing Authorization for PROVENGE in Europe
Date:1/7/2011

stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE.  Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NIAGARA FALLS, N.Y., Jan. 15, 2014   Niagara ... has been selected by Buffalo BioBlower Technologies LLC ("B3") ... its SBIR Phase 2 award from the Army Corps ... purification system that kills all biological contaminants and destroys ...
(Date:1/15/2014)... 15, 2014 This webinar will focus ... clinical safety assessment in biosimilars. , Regulatory frameworks are ... drug development, however the complex nature of biopharmaceuticals makes ... and efficacy extremely challenging. Based on the specific aspects ...
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... PharmAthene, Inc. (NYSE Amex: PIP ) ... the development of its second generation anthrax vaccine, SparVax™. ... 100 liter scale and demonstrating 36 month stability, the ... 1,500 liter engineering production run for SparVax™.  As a ...
... Sept. 9, 2011 Palatin Technologies, Inc. (NYSE Amex: ... the Rodman & Renshaw Annual Global Investment Conference on Tuesday, ... will be held at The Waldorf Astoria in New York, ... Executive Officer of Palatin Technologies, will provide an update on ...
... England, September 9, 2011 PharmaVentures ... to announce that they have been engaged by ... a buyer for an established full service CMC ... Pleasanton, California. The engagement will utilise PharmaVentures, asset ...
Cached Biology Technology:PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 2PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 3PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program 4
(Date:7/9/2014)... of the puzzle behind nature,s ability to split ... advance the development of artificial photosynthesis for clean, ... an international collaboration of scientists led by researchers ... and the SLAC National Accelerator Laboratory. , ... the world,s most powerful x-ray laser, the researchers ...
(Date:7/9/2014)... children with traumatic injuries have identified an immune ... develop a hospital-acquired infection. The study, led by ... in June in the journal Shock , ... lead to the clinical implementation of quick-turnaround immune ... immune system damage following critical illness or injury ...
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bee foraging chronically impaired by pesticide exposure: Study 2
... and vegetables that are rich in nitrates protect the ... nitrates into nitrites by the bacteria in the oral ... in the stomach. The Swedish researcher Joel Petersson has ... can be harmful for the stomach. "Nitrates in ...
... behind mad cow disease and its human variation, Creutzfeldt-Jakob ... findings from Gerald Zamponi and colleagues, normally functioning prions ... appear in the May 5th issue of the Journal ... when the prion protein adopts an abnormal conformation. This ...
... in Support of "New Employee,Verification Act", ALEXANDRIA, ... to human resource management today led a coalition ... "New Employee,Verification Act." In testimony today before the ... Meisinger, President and CEO of SHRM,urged legislators to ...
Cached Biology News:Nitrates in vegetables protect against gastric ulcers 2Nitrates in vegetables protect against gastric ulcers 3Nitrates in vegetables protect against gastric ulcers 4Nitrates in vegetables protect against gastric ulcers 5SHRM CEO Testifies Before House Subcommittee on Social Security 2SHRM CEO Testifies Before House Subcommittee on Social Security 3
...
...
... Novagen's frozen Sf9 Insect Cells are derived from ... pretested for optimal growth, use in transfections, plaque ... are frozen in a protocol that optimizes recovery ... for growth in serum-free BacVector Insect Cell Medium ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: